ADHD clinical trials

Explore recruiting adhd clinical trials.

Recruiting adhd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

ADHD trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Effectiveness of methylphenidate in children and adolescents with KBG syndrome: An N-of-1 series

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Elvanse (lisdexamfetamine dimesylate) 70 mg hard capsules, Marketing Authorization Holder: Takeda Pharmaceuticals International AG Ireland Branch, Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, in healthy adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients with Tourette Syndrome – Allevia 2

Spain, France, Poland, Hungary, Belgium, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 10 mg, manufactured by Ohm Laboratories Inc. (A Sun Pharma Company), 14 Terminal Road, New Brunswick, 08901, NJ, USA with Vyvanse (Lisdexamfetamine Dimesylate) 10 mg capsules; Product of Takeda Canada Inc., Toronto Ontario ON M5H 4E3, Canada, in healthy adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

ADHD trials by city

ADHD in Toronto ADHD in Vancouver ADHD in Montreal ADHD in Calgary ADHD in Edmonton ADHD in Ottawa ADHD in Winnipeg ADHD in Quebec City ADHD in Hamilton ADHD in Kitchener ADHD in London ADHD in Halifax ADHD in New York ADHD in Los Angeles ADHD in Chicago ADHD in Houston

Other conditions

ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia Depression Anxiety Bipolar disorder Schizophrenia PTSD OCD Insomnia Postpartum depression Alcohol use disorder Substance use disorder COPD Asthma Long COVID Cystic fibrosis Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease